DMTK.Q Stock Overview
A molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
DermTech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$1.73 |
| 52 Week Low | US$0.000001 |
| Beta | 1.98 |
| 1 Month Change | 0% |
| 3 Month Change | -99.99% |
| 1 Year Change | -100.00% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%
May 21
We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate
Mar 02Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%
Mar 02Revenues Working Against DermTech, Inc.'s (NASDAQ:DMTK) Share Price
Dec 28Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky
Sep 18Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?
Jun 14Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023
May 10DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%
May 06We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jan 16Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)
Nov 08Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?
Oct 11DermTech grants stock options
Oct 11Diving Into DermTech
Sep 01Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80
Aug 10DermTech: Approaching An All Or Nothing Moment
Jun 13We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jun 04DermTech - Taking A Second Look At The Growth Thesis
Mar 31DermTech: Adoption Headwinds And Earnings Misses
Dec 23Companies Like DermTech (NASDAQ:DMTK) Are In A Position To Invest In Growth
Dec 02Shareholder Returns
| DMTK.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 0.2% | -0.2% |
| 1Y | -100.0% | -4.7% | 25.6% |
Return vs Industry: DMTK.Q underperformed the US Biotechs industry which returned -4.7% over the past year.
Return vs Market: DMTK.Q underperformed the US Market which returned 25.6% over the past year.
Price Volatility
| DMTK.Q volatility | |
|---|---|
| DMTK.Q Average Weekly Movement | 4,159.8% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 18.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DMTK.Q's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: DMTK.Q's weekly volatility has increased from 2057% to 4160% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 207 | n/a | www.dermtech.com |
DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions.
DermTech, Inc. Fundamentals Summary
| DMTK.Q fundamental statistics | |
|---|---|
| Market cap | US$35.00 |
| Earnings (TTM) | -US$89.63m |
| Revenue (TTM) | US$15.66m |
0.0x
P/S Ratio0.0x
P/E RatioIs DMTK.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMTK.Q income statement (TTM) | |
|---|---|
| Revenue | US$15.66m |
| Cost of Revenue | US$14.33m |
| Gross Profit | US$1.33m |
| Other Expenses | US$90.96m |
| Earnings | -US$89.63m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.54 |
| Gross Margin | 8.51% |
| Net Profit Margin | -572.19% |
| Debt/Equity Ratio | 0% |
How did DMTK.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/04 11:31 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
DermTech, Inc. is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sally Yanchus | Brookline Capital Markets |
| Mark Massaro | BTIG |
| Alexander Nowak | Craig-Hallum Capital Group LLC |